Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

Executive Summary

Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.

Advertisement

Related Content

Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
Year's First 4 IPOs Go South As Proteostasis, AveXis Launch
FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
IPO UPDATE: Bubble worries heighten after another big Alzheimer's offering
Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash
Lilly and Novartis put VC cash into Aeglea's series B
TABLE: In turbulent week, 2 IPOs price, 6 test waters
Zeria/Tillotts in $100m-plus deal for CPP's FAP drug
Novartis Option Fund licenses option on Viamet's metalloenzyme programme

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel